Cipla Limited (CIPLA.NS)
- Previous Close
1,480.00 - Open
1,478.00 - Bid --
- Ask --
- Day's Range
1,462.20 - 1,516.90 - 52 Week Range
1,335.00 - 1,702.05 - Volume
1,706,189 - Avg. Volume
1,446,036 - Market Cap (intraday)
1.221T - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
24.49 - EPS (TTM)
61.72 - Earnings Date May 13, 2025
- Forward Dividend & Yield 13.00 (0.88%)
- Ex-Dividend Date Aug 2, 2024
- 1y Target Est
1,640.92
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
www.cipla.com27,764
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: CIPLA.NS
View MorePerformance Overview: CIPLA.NS
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CIPLA.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CIPLA.NS
View MoreValuation Measures
Market Cap
1.19T
Enterprise Value
1.11T
Trailing P/E
23.97
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.49
Price/Book (mrq)
4.21
Enterprise Value/Revenue
4.17
Enterprise Value/EBITDA
14.63
Financial Highlights
Profitability and Income Statement
Profit Margin
18.67%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
267.2B
Net Income Avi to Common (ttm)
49.9B
Diluted EPS (ttm)
61.72
Balance Sheet and Cash Flow
Total Cash (mrq)
87.08B
Total Debt/Equity (mrq)
1.62%
Levered Free Cash Flow (ttm)
--